S&P 500   3,856.27 (+0.02%)
DOW   30,983.15 (+0.07%)
QQQ   329.09 (+0.30%)
AAPL   142.28 (-0.45%)
MSFT   233.48 (+1.72%)
FB   283.54 (+1.99%)
GOOGL   1,907.01 (+0.67%)
AMZN   3,328.48 (+1.05%)
TSLA   884.68 (+0.44%)
NVDA   542.57 (-0.65%)
BABA   263.00 (+0.62%)
CGC   35.45 (+7.72%)
GE   11.64 (+5.91%)
MU   81.63 (+0.43%)
AMD   95.25 (+1.19%)
NIO   59.35 (-1.07%)
T   29.37 (+0.89%)
F   11.34 (+0.44%)
ACB   10.64 (+4.72%)
BA   203.95 (+0.29%)
DIS   170.61 (-0.74%)
NFLX   565.99 (+1.65%)
GILD   67.17 (-1.45%)
S&P 500   3,856.27 (+0.02%)
DOW   30,983.15 (+0.07%)
QQQ   329.09 (+0.30%)
AAPL   142.28 (-0.45%)
MSFT   233.48 (+1.72%)
FB   283.54 (+1.99%)
GOOGL   1,907.01 (+0.67%)
AMZN   3,328.48 (+1.05%)
TSLA   884.68 (+0.44%)
NVDA   542.57 (-0.65%)
BABA   263.00 (+0.62%)
CGC   35.45 (+7.72%)
GE   11.64 (+5.91%)
MU   81.63 (+0.43%)
AMD   95.25 (+1.19%)
NIO   59.35 (-1.07%)
T   29.37 (+0.89%)
F   11.34 (+0.44%)
ACB   10.64 (+4.72%)
BA   203.95 (+0.29%)
DIS   170.61 (-0.74%)
NFLX   565.99 (+1.65%)
GILD   67.17 (-1.45%)
S&P 500   3,856.27 (+0.02%)
DOW   30,983.15 (+0.07%)
QQQ   329.09 (+0.30%)
AAPL   142.28 (-0.45%)
MSFT   233.48 (+1.72%)
FB   283.54 (+1.99%)
GOOGL   1,907.01 (+0.67%)
AMZN   3,328.48 (+1.05%)
TSLA   884.68 (+0.44%)
NVDA   542.57 (-0.65%)
BABA   263.00 (+0.62%)
CGC   35.45 (+7.72%)
GE   11.64 (+5.91%)
MU   81.63 (+0.43%)
AMD   95.25 (+1.19%)
NIO   59.35 (-1.07%)
T   29.37 (+0.89%)
F   11.34 (+0.44%)
ACB   10.64 (+4.72%)
BA   203.95 (+0.29%)
DIS   170.61 (-0.74%)
NFLX   565.99 (+1.65%)
GILD   67.17 (-1.45%)
S&P 500   3,856.27 (+0.02%)
DOW   30,983.15 (+0.07%)
QQQ   329.09 (+0.30%)
AAPL   142.28 (-0.45%)
MSFT   233.48 (+1.72%)
FB   283.54 (+1.99%)
GOOGL   1,907.01 (+0.67%)
AMZN   3,328.48 (+1.05%)
TSLA   884.68 (+0.44%)
NVDA   542.57 (-0.65%)
BABA   263.00 (+0.62%)
CGC   35.45 (+7.72%)
GE   11.64 (+5.91%)
MU   81.63 (+0.43%)
AMD   95.25 (+1.19%)
NIO   59.35 (-1.07%)
T   29.37 (+0.89%)
F   11.34 (+0.44%)
ACB   10.64 (+4.72%)
BA   203.95 (+0.29%)
DIS   170.61 (-0.74%)
NFLX   565.99 (+1.65%)
GILD   67.17 (-1.45%)
Log in
NASDAQ:ACST

Acasti Pharma Stock Forecast, Price & News

$0.72
-0.04 (-5.25 %)
(As of 01/26/2021 10:51 AM ET)
Add
Compare
Today's Range
$0.71
Now: $0.72
$0.77
50-Day Range
$0.25
MA: $0.44
$0.83
52-Week Range
$0.17
Now: $0.72
$1.09
Volume114,836 shs
Average Volume87.89 million shs
Market Capitalization$69.59 million
P/E RatioN/A
Dividend YieldN/A
Beta2.45
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.

MarketRank

Overall MarketRank

1.18 out of 5 stars

Medical Sector

840th out of 1,922 stocks

Pharmaceutical Preparations Industry

423rd out of 771 stocks

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACST
CUSIPN/A
Phone45-0686-4555
Employees32
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.14 per share

Profitability

Net Income$-25,510,000.00

Miscellaneous

Market Cap$69.59 million
Next Earnings Date2/12/2021 (Estimated)
OptionableNot Optionable
$0.72
-0.04 (-5.25 %)
(As of 01/26/2021 10:51 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions

How has Acasti Pharma's stock been impacted by Coronavirus?

Acasti Pharma's stock was trading at $0.3849 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACST shares have increased by 90.8% and is now trading at $0.7342.
View which stocks have been most impacted by COVID-19
.

Is Acasti Pharma a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Acasti Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACST, but not buy additional shares or sell existing shares.
View analyst ratings for Acasti Pharma
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Acasti Pharma?

Wall Street analysts have given Acasti Pharma a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Acasti Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Acasti Pharma's next earnings date?

Acasti Pharma is scheduled to release its next quarterly earnings announcement on Friday, February 12th 2021.
View our earnings forecast for Acasti Pharma
.

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) announced its quarterly earnings results on Monday, November, 16th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02.
View Acasti Pharma's earnings history
.

What price target have analysts set for ACST?

5 brokerages have issued 12-month price targets for Acasti Pharma's shares. Their forecasts range from $0.50 to $7.00. On average, they expect Acasti Pharma's share price to reach $2.81 in the next year. This suggests a possible upside of 282.7% from the stock's current price.
View analysts' price targets for Acasti Pharma
or view Wall Street analyst' top-rated stocks.

Are investors shorting Acasti Pharma?

Acasti Pharma saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 506,800 shares, a decrease of 40.7% from the December 15th total of 854,400 shares. Based on an average daily volume of 16,340,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.5% of the shares of the stock are short sold.
View Acasti Pharma's Short Interest
.

Who are some of Acasti Pharma's key competitors?

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the following people:
  • Ms. Janelle D' Alvise, Pres, CEO, Corp. Sec. & Director (Age 65, Pay $565.48k)
  • Dr. Pierre Lemieux, Co-Founder, COO & Chief Scientific Officer (Age 55, Pay $344.15k)
  • Mr. Brian James Groch, Chief Commercial Officer (Age 53, Pay $376.62k)
  • Mr. Brian D. Ford CPA, CA, Chief Financial Officer

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."

How do I buy shares of Acasti Pharma?

Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately $0.73.

How big of a company is Acasti Pharma?

Acasti Pharma has a market capitalization of $71.14 million. The biopharmaceutical company earns $-25,510,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Acasti Pharma employs 32 workers across the globe.

What is Acasti Pharma's official website?

The official website for Acasti Pharma is www.acastipharma.com.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5. The biopharmaceutical company can be reached via phone at 45-0686-4555 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.